Heart Failure Clinical Trial
Official title:
Impact of Vericiguat on Vascular Biology, as Well as Resting and Exertional Cardiovascular Performance Among Patients With Heart Failure With Reduced Ejection Fraction
Vericiguat is a new drug that was recently approved by the Food and Drug Administration for patients with heart failure. In a large randomized controlled trial, this drug was found to help patients with heart failure live longer and stay out of the hospital more than normal treatment for heart failure. However, it is unclear how this drug positively impacts "hemodynamics", meaning how the heart functions during activity/exercise, and how it may also help blood pressure and health of the blood vessels and autonomic nervous system. This study, funded by the drug manufacturer, Merck Corp, will enroll 30 patients with heart failure. The patients will undergo baseline testing, and then be randomized to either receive vericiguat or a placebo for about three months, and then come back for follow-up testing to learn more about how the drug impacts heart function.
Vericiguat is an oral soluble guanylate cyclase (sGC) stimulator, which enhances sGC sensitivity to nitric oxide (NO). Patients with heart failure with reduced ejection fraction (HFrEF) are known to have a reduction in NO bioavailability as a result of endothelial dysfunction, oxidative stress2 and presence of reactive oxygen species. In turn, there is a reduction in sGC activity, which is associated with multiple adverse cardiac effects, including cardiac stiffness and fibrosis, microvascular dysfunction and ultimately, propagation of HFrEF. In a large, multi-center randomized placebo controlled trial, vericiguat reduced the incidence of death from cardiovascular causes or hospitalization for heart failure. The VICTORIA trial demonstrated that on a larger scale (N=5050 patients), modulation of the NO-sGC pathway led to stabilization and improvement of the heart failure syndrome, which translated into improvements in hard outcomes. There are a paucity of data, however, characterizing the direct effects of vericiguat on left ventricular function among humans suffering from HFrEF. The echocardiographic substudy of VICTORIA found that left ventricular ejection fraction (LVEF) improved from baseline to 8 months follow-up in both the placebo arm (31.8±8.2% to 34.2±9.2%, P<0.001) and the vericiguat arm (33.0±9.4% to 36.1±10.1%, P<0.001) and that LV end-systolic volume index (LVESVI) also declined in both arms. However, non-invasive, echocardiographic-derived metrics of ventricular function are relatively insensitive when compared to invasive determinants of overall cardiovascular performance. Thus, longitudinal changes in metrics such as LVEF and LVESVI, while informative, may not sufficiently characterize the physiologic adaptations that occur following modulation of the NO-sGC pathway, which in turn, translate into improvements in hard outcomes, which were observed in the VICTORIA trial. The primary objective of this proposal is to precisely characterize the impact of NO-sGC modulation with the novel agent vericiguat on vascular biology, as well as resting and exertional cardiovascular performance among patients with heart failure with reduced ejection fraction (HFrEF). Our central hypothesis is that vericiguat improves endothelial function, which promotes arterial vasodilatation - and consequently, reduces left and right ventricular afterload. This reduction in afterload improves ventricular contractility, and in turn, reduces HFrEF severity by improving left and right-sided cardiovascular performance. This hypothesis will be tested through comprehensive assessment of longitudinal changes in vascular biology and cardiopulmonary performance among patients with HFrEF prior to, and following initiation of the novel oral sGC stimulator, vericiguat. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|